结直肠癌患者血清SFRP1基因甲基化的检测及临床意义  

Detection and significance of serum SFRP1 promoter methylation status in patients with colorectal cancer

作　　者：董丽钧[1] 顾晓怡[1] 姜藻[1] 

机构地区：[1]东南大学附属中大医院肿瘤科,南京市210009

出　　处：《江苏医药》2010年第18期2153-2155,共3页Jiangsu Medical Journal

摘　　要：目的检测分泌型卷曲相关蛋白1(SFRP1)基因在结直肠癌(CRC)患者血清中的甲基化状态,分析其临床意义。方法留取72例CRC患者术前血清标本及40例肠道良性病变血清标本,甲基化特异性聚合酶链反应(MS-PCR)检测SFRP1基因启动子区域甲基化状况。结果 72例CRC血清中,SFRP1基因甲基化比例为55.6%(40/72),而40例肠道良性病变患者中有4例发生甲基化(10.0%)(P<0.01)。SFRP1基因甲基化与患者临床病理特征及CEA、CA19-9水平无相关性。联合检测血清SFRP1甲基化及CEA、CA19-9水平可显著提高CRC检出率。结论血清SFRP1基因甲基化可望成为CRC诊断的新型分子标记,与传统肿瘤标记物的联合可进一步提高诊断率。Objective To study the detection and significance of serum secreted frizzled-related protein 1（SFRP1） gene promoter methylation status in patients with colorectal cancer（CRC）.MethodsGenomic DNA was extracted from peripheral blood of 72 CRC patients and 40 controls with benign colorectal diseases.Promoter methylation status of SFRP1 gene was determined by methylation-specific polymerase chain reaction（MS-PCR）.Results The percentage of aberrant methylation of SFRP1 gene was 55.6%（40/72） in CRC patients,which was higher than 10.0%（4/40） in the controls（P0.01）.SFRP1 hypermethylation status was not correlated with clinicopathological parameters and CEA/CA19-9 levels in CRC patients.Combined analysis of serum CEA,CA19-9 and SFRP1 methylation could increase the detection rate for CRC diagnosis.Conclusion Serum SFRP1 methylation may be an useful biomarker in the diagnosis of CRC.Combined analysis of serum CEA,CA19-9 and SFRP1 methylation could increase the detection rate for CRC.

关 键 词：结直肠癌 分泌型卷曲相关蛋白1 

分 类 号：R735[医药卫生—肿瘤]